Compare CNSP & DLXY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNSP | DLXY |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | Singapore |
| Employees | N/A | 11 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.2M |
| IPO Year | 2019 | N/A |
| Metric | CNSP | DLXY |
|---|---|---|
| Price | $4.75 | $0.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 13.3K | ★ 357.4K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.23 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.34 |
| 52 Week High | $10.59 | $7.00 |
| Indicator | CNSP | DLXY |
|---|---|---|
| Relative Strength Index (RSI) | 57.59 | 44.94 |
| Support Level | $4.50 | $0.35 |
| Resistance Level | $5.61 | $0.95 |
| Average True Range (ATR) | 0.33 | 0.08 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 97.50 | 28.97 |
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
Delixy Holdings Ltd a holding company. Through its subsidiary, it is principally engaged in the trading of oil-related products, which are broadly categorized into crude oil and oil-based products, including naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. These products are traded across multiple countries in Southeast Asia, East Asia, and the Middle East, and the Group has established a presence in the oil trading markets in these countries. The majority of the Group's revenue is generated from the trading of crude oil. Geographically, it derives maximum revenue from its business in East Asia.